Intercept Pharmaceuticals Stock News

Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) shares are up 30% after announcing an agreement to sell some of its foreign subsidiaries plus rights to its international operation, including the Ocaliva

Intercept (ICPT) delivered earnings and revenue surprises of 34.83% and 2.51%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) has agreed to sell certain foreign subsidiaries and rights regarding its international operations, including a license to commercialize Ocaliva (obetich

Intercept Pharmaceuticals (ICPT) stock is soaring higher on Thursday after the biopharmaceutical company revealed a deal with Advanz Pharma. The post Why Is Intercept Pharmaceuticals (ICPT) Stock Up T

Intercept (ICPT) lead drug Ocaliva holds ground amid challenges. A positive readout from the NASH studies will be a good boost for the stock in the year ahead.

Intercept (ICPT) lead drug Ocaliva holds ground amid challenges. A positive readout from the NASH studies will be a good boost for the stock in the year ahead.

Big biopharma companies usually rely on M&A to get immediate access to a new class of drug or technology, fill in the gap in their pipeline and compensate for revenue loss from patent expiration of bl

Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -6.74% and 9.68%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the st

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock?

Denali Therapeutics Inc. (DNLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be

Short-squeeze stocks continue to be a hot topic with retail traders and we're going over the top ones to keep an eye on for Tuesday! The post Short-Squeeze Stocks: Top 10 Stocks With High Short Intere

Intercept Pharmaceuticals is likely to have a pre-submission meeting with the FDA of Ocaliva for NASH in H1 '22. How would ICPT stock react? Find out.

Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH

Analysts have provided the following ratings for Intercept Pharmaceuticals (NASDAQ:ICPT) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2